Related Experiment Video
Updated: Aug 8, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
CCK1 antagonists: are they ready for clinical use?
Shajan A S Peter1, Massimo D'Amato, Christoph Beglinger
1Department of Gastroenterology, University Hospital, Basel, Switzerland.
Cholecystokinin (CCK) acts as both a hormone and neurotransmitter, regulating gastrointestinal functions and food intake. CCK1 antagonists show promise for treating GERD, IBS, pancreatitis, and other gastrointestinal disorders.
Area of Science:
- Gastroenterology
- Neurogastroenterology
- Pharmacology
Background:
- Cholecystokinin (CCK) is a peptide hormone and neurotransmitter found in the gastrointestinal tract and central nervous system.
- Its dual location underlies its role in regulating both motor and sensory functions of the digestive system, including food intake.
Purpose of the Study:
- To review recent advances in understanding the biological role of CCK.
- To focus on the clinical and therapeutic potential of CCK1 receptor antagonists in gastroenterology.
Main Methods:
- Literature review of biological, pharmacological, clinical, and therapeutic research on CCK and its antagonists.
- Emphasis on recent advances and future research directions.
Main Results:
- CCK regulates gastrointestinal motility, secretion, and food intake via CCK1 and CCK2 receptors.
- CCK1 antagonists have shown potential in treating GERD, IBS, pancreatitis, sphincter of Oddi dysfunction, and gastrointestinal cancers.
Conclusions:
- CCK plays a critical role in gastrointestinal physiology.
- CCK1 antagonists represent a promising therapeutic strategy for various gastrointestinal conditions, warranting further investigation.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:46A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors
Published on: December 2, 2022
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers